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The pharmacological activity of insulin-loaded dextran sulfate/chitosan nanoparticles was evaluated following
oral dosage in diabetic rats. Nanoparticles were mucoadhesive and negatively charged with a mean size of 500
nm, suitable for uptake within the gastrointestinal tract. Insulin association efficiency was over 70% and was
released in a pH-dependent manner under simulated gastrointestinal conditions. Orally delivered nanoparticles
lowered basal serum glucose levels in diabetic rats around 35% with 50 and 100 IU/kg doses sustaining
hypoglycemia over 24 h. Pharmacological availability was 5.6 and 3.4% for the 50 and 100 IU/kg doses,
respectively, a significant increase over 1.6%, determined for oral insulin alone in solution. Confocal microscopic
examinations of FITC-labeled insulin nanoparticles showed adhesion to rat intestinal epithelium, and internalization
of insulin within the intestinal mucosa. Encapsulation of insulin into dextran sulfate/chitosan nanoparticles was
a key factor in the improvement of the bioavailability of its oral delivery over insulin solution.
Introduction
Among the controlled release formulations, polymeric col-
loidal systems have shown a certain degree of success for the
oral delivery of therapeutic proteins like insulin,1,2 calcitonin,3
octeotride,4 and cyclosporine,5 among others. Nanoparticles
formulated from natural polymers like alginate, agar, agarose,
chitosan, or synthetic polymers such as poly(lactic acid), poly-
(lactic-co-glycolic acid), poly(-caprolactone), and poly(phos-
phoesters) have attracted significant interest as protein carriers.6-8
The gastrointestinal (GI) uptake of proteins like insulin can
be improved by association to nanoparticles, mainly to protect
insulin from degradation in the GI tract. Low pH and protease
hydrolysis have demonstrated to be an important limitation to
intestinal absorption of intact insulin9 and transport into systemic
circulation.6 These carriers have been improving oral peptide
delivery due to their prolonged retention in the GI tract and
excellent penetration into the mucus layer.10 Further, they are
able to be taken up by the M cells of the Peyer’s patches, a
type of lymphatic island within the intestinal tract that represents
the major gateway through which nanoparticles may be ab-
sorbed.11 However, the mechanisms by which nanoparticles
based on natural polysaccharides have improved the oral
absorption of proteins still needs further elucidation.12
Polysaccharides are natural biodegradable hydrophilic poly-
mers, which exhibit enzymatic degradation behavior and good
biocompatibility. They can also form polyelectrolyte complexes
by electrostatic interactions between oppositely charged groups
resulting in ion-pairing without altering the integrity of the
polymer.13 Nanoparticle delivery systems that have been
developed by employing natural polysaccharides have the
potential to retain protein stability, increase the duration of the
therapeutic effect of proteins as well as the possibility of
administration through nonparenteral routes.14 Such polymers
can be easily modified chemically and biochemically, and are
highly stable, safe, nontoxic, with gel forming properties,
suggesting their suitability to be used for oral protein delivery.15
Chitosan (Chit), the most widely employed natural polysaccha-
ride, is able to reduce the transepithelial electrical resistance,
promoting the passage of small electrolytes and transiently
opening tight conjunction between epithelial cells16 and to
combine with anionic sialic acid residues of the intestinal
mucosa17 due to mucoadhesive properties. The adhesion of Chit
at the site of insulin GI absorption may offer various advantages
for its uptake.18,19 Previous work with Chit coated alginate
nanoparticles20 and other Chit-based nanoparticles2,21 demon-
strated their potential to orally administer insulin, but those
formulations also showed premature gastric insulin release,
exposing insulin to undesired GI degradation.
Dextran sulfate (DS) is a biodegradable and biocompatible
branched negatively charged polyanion able to strongly interact
with positively charged proteins. Chit and DS have been
complexed to formulate different drug delivery systems,22-25
but their application to oral delivery of proteins has not been
explored. They are intrinsically hydrophilic, which may con-
tribute to the encapsulation of water-soluble proteins and to
promote longer circulation times in ViVo. Recently, we formu-
lated insulin into DS/Chit nanoparticles, which fully retained
insulin in simulated gastric medium, and sustained the release
up to 24 h in simulated intestinal medium, while preserving its
bioactivity.26
The main objective of the present study was to determine
whether insulin encapsulated in DS/Chit nanoparticles induced
a hypoglycemic effect after oral administration to diabetic rats.
The use of a single nanoparticle administration is the most
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common way of evaluating the oral insulin bioavailability,
mostly because this assay is performed in fasted animals.
Prolonged assay times could lead to false decrease of blood
glucose levels due to absence of food.27 Moreover, it was
demonstrated that blood glucose levels of diabetic rats can be
effectively controlled by insulin-loaded microparticle adminis-
tration, following either single or multiple oral administration.28
Also, to predict the mechanism of insulin absorption from the
GI tract, fluorescent-labeled insulin associated with nanoparticles
was examined.
Experimental Section
Materials. Low MW Chit (50 kDa), degree of acetylation 15%,
was purchased from Sigma. High MW DS (500 kDa) was obtained
from PKC. DS stock solutions were prepared in deionized water (Milli-
Q) overnight under magnetic stirring and Chit was dissolved in 1%
acetic acid solution in deionized water followed by filtering using a
Millipore #2 paper filter and stored at 4 °C. Human crystalline zinc-
insulin (Lot RS0325, 7.0 mg lyophilized human biosynthetic insulin
per vial) was a gift from Lilly Portugal. Wistar male rats weighing
200-250 g, were provided by Charles River, Barcelona, Spain.
Streptozocin and Insulin-FITC from bovine pancreas were from Fluka.
Alexa Fluor 594 was from Molecular Probes. Human insulin detecting
ELISA kits were from Linco.
Methods
Preparation of Nanoparticles. Optimized conditions to obtain DS/
Chit nanoparticles were established previously.26 Briefly, nanoparticle
complexation between DS and Chit was performed by employing
aqueous solutions of oppositely charged polymers in a final volume of
120 mL. Unless otherwise mentioned, complexes were obtained after
dropwise addition of Chit solution at pH 5.0 to DS solution at pH 3.2
under magnetic stirring followed by additional mixing for 15 min at
600 rpm to final concentrations of 0.15% DS and 0.10% Chit (DS:
Chit mass ratio 1.5:1). For insulin encapsulation, the protein was
previously dissolved in DS solution before Chit complexation.
Nanoparticle Characterization. Particle size was measured by
photon correlation spectroscopy (PCS) at 25 °C with a detection angle
of 90° and œ potential by laser doppler anemometry (LDA) using a
Malvern Zetasizer and Particle Analyzer 5000 (Malvern Instruments)
(n g 6).
Morphology was evaluated by placing samples in a grid, treating
with uranil acetate and observing under a Zeiss TEM (model 902A).
Association efficiency (AE) as the amount of insulin associated with
the particles was calculated by the difference between the total amount
used to prepare the particles, and the amount of residual insulin in the
supernatant after particle centrifugation. The difference between the
total initial insulin and the amount of unassociated residual after particle
separation, as the percentage of total nanoparticle dry mass is referred
to as loading capacity (LC) ()3).
Insulin Release from Nanoparticles. Insulin-loaded nanoparticles
(200 mg) were placed into 20 mL of HCl buffer at pH 1.2 (USP
XXVIII) and incubated at 37 °C for 2 h under magnetic stirring at 100
rpm. At determined times, 0.4 mL samples were taken for insulin
determination and replaced by fresh medium. After 2 h, the same
nanoparticles were isolated by centrifugation (20000g/15 min) and were
transferred to 20 mL of phosphate buffer at pH 6.8 (USP XXVIII) and
incubated at 37 °C for an additional 4 h under magnetic stirring at 100
rpm. At determined times, 0.4 mL samples were taken for insulin
determination and replaced by fresh medium. Release assays were
performed in triplicate.
Insulin Determination. Insulin concentration was determined spec-
trophotometrically using the Coomassie PlusTM (Pierce, Rockford,
MD) modified Bradford assay.29 Briefly, insulin samples and Bradford
reagent were mixed at 1:1 v/v ratio in a 96-well plate and incubated at
room temperature for 15 min. The absorbance was measured at 595
nm on a thermomax plate reader (PowerWaveX; Bio-Tek, Winooski,
VT). Calibration curves were made using supernatant of unloaded
Table 1. Characterization of DS/Chit Nanoparticles Produced with Two Different DS:Chit Mass Ratios (1.5:1 and 1:1.5) in Terms of Mean
Nanoparticle Size, œ Potential, and Insulin AE and LC (n ) 3, Mean ( SD)
size (nm) œ potential (mV) AE (%) LC (%)
insulin-loaded nanoparticles (1.5:1) 527 ( 103 -20.6 ( 4.8 69.3 ( 1.3 2.3 ( 0.6
insulin-loaded nanoparticles (1:1.5) 1577 ( 230a 11.5 ( 7.5 24.0 ( 1.7a 2.0 ( 1.5
a Statistically significant between groups (p < 0.05).
Figure 1. TEM image of DS/Chit nanoparticles (DS:Chit mass ratio
of 1.5:1).
Figure 2. Insulin release from insulin DS/Chit nanoparticles produced
with a DS:Chit mass ratio of 1.5:1 in gastric pH 1.2 simulated fluid
for 2 h followed by additional 4 h in intestinal pH 6.8 simulated fluids
at 37 °C (mean ( SD, n ) 3).
Figure 3. Plasma glucose levels after administration of insulin-loaded
nanoparticles produced with a DS:Chit mass ratio of 1.5:1 insulin-
loaded 50 (b) and 100 (2) IU/kg and empty nanoparticles (0),
compared to 2.5 IU/kg delivered subcutaneously (O). Data represent
the mean ( SEM, n ) 6 per group. *100 IU/kg dose showed
statistically significant differences from negative empty nanoparticle
control (p < 0.05).
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particles for AE and unloaded nanoparticles for in Vitro release profile.
All the assays were performed in triplicate.
Insulin Pharmacological Activity. Insulin pharmacological activity
was determined in diabetic rats following the protocol described
previously.30 Nanoparticles with DS:Chit mass ratios of 1.5:1 and 1:1.5
were administered at insulin doses of 50 or 100 IU/kg. Control rats
were administered an equivalent volume of insulin solution (50 IU/
kg), or a suspension of empty nanoparticles in insulin solution (50 IU/
kg), or a dispersion of blank nanoparticles. The volume of dispersion
and controls administered was 1.0 mL and formulations were diluted
in pH 4.5 phosphate buffer whenever required. Also, a control using
subcutaneously injected insulin (2.5 IU/kg) was used. Aliquots were
collected before and during 24 h period following administration.
Plasma glucose levels were plotted against time to evaluate the
cumulative hypoglycemic effect over time after insulin administration,
quantified by the area above the curve (AAC), determined using the
trapezoidal method. Pharmacological availability (PA) of peroral insulin
loaded into nanoparticles and in solution was determined as the relative
measure of the cumulative reduction in glucose blood levels compared
to a 100% availability of the control insulin administered subcutaneously
at a dose of 2.5 IU/kg. Plasma insulin levels were plotted against time
to evaluate the cumulative amount of insulin delivered to the plasma
after insulin administration, quantified by area under the curve (AUC).
Plasma glucose level was determined using the Medisense Precision
Xceed Kit (Abbot, range 10-600 mg/dL) and expressed as the
percentage of the baseline plasma glucose level. The serum insulin
concentration was measured by ELISA. Results are shown as the mean
((SD) of at least six animals.
Tracking FITC-Labeled Nanoparticles. Fluorescein (FITC)-labeled
insulin was loaded into nanoparticles to yield 2.0 mg of FITC-insulin/
mL of nanoparticle suspension and administered by oral gavage (150
mg of nanoparticles diluted in 1.0 mL of pH 4.5 phosphate buffer) to
Wistar diabetic rats fasted overnight. The rats were sacrificed 3 h later
and intestinal segments localized after laparotomy. After washing with
isotonic saline, intestinal epithelial cell membranes were stained with
Alexa Fluor 594 (0.05% in PBS:glycerol 1:1) for 1 h. Tissue was rinsed,
mounted on glass slides and observed using a confocal laser scanning
microscope (Leica). Tissue samples were scanned in the x,y plane with
a z-step of 500 nm. Because the spectra are not overlapping, FITC-
insulin and Alexa Fluor could be analyzed simultaneously with 488
and 561 nm laser, respectively. Control rats were dosed with FITC-
insulin solution or empty nanoparticles.
Statistical Analysis. A one-way analysis of variance (ANOVA) was
used to evaluate group comparison. If the group by each time interaction
was significantly different (p < 0.05), differences between groups were
compared within a post-hoc test (S-N-K). All statistical analyses were
performed with the SPSS software package (SPSS for Windows 14.0,
SPSS, Chicago, IL).
Results and Discussion
DS/Chit colloidal nanoparticles were developed and optimized
to encapsulate insulin for oral delivery.26 The mucoadhesive
and absorption enhancement properties of Chit and the protective
effect of DS against insulin release at low pH were combined
to promote and ensure insulin intestinal absorption. Low MW
and low degree of acetylation Chit was used because it was
previously demonstrated that lower molar mass Chit leads to
smaller particle size by polyelectrolyte complexation and low
acetyl content favors the formation of less swollen particles.
High MW DS was used as it resulted in more stable colloidal
nanoparticles.13,31 Nanoparticles prepared with DS:Chit of 1.5:1
showed size around 500 nm (Table 1), resulting in a dense
matrix with irregular spherical structure as seen in Figure 1.
This irregular and highly aggregated structure is attributed to a
strong interaction between polyions,31,32 occurring rapidly by
random incorporation of different polymeric chains into the
particle structure.
The œ potential was less negative after encapsulation of insulin
(-20.6 against -24.5 mV for insulin-free nanoparticles, Table
1), probably due to the localization of some insulin on the
surface on the nanoparticles. At pH 5 used for nanoparticle
formulation, insulin is positively charged, affecting the surface
charge of the nanoparticles, although to a small extent because
of low loading. The AE found was 69.3% (Table 1), higher
than that obtained with Chit nanoparticles without DS com-
plexation.2,33 Particles with a DS:Chit mass ratio of 1:1.5 were
also prepared, presenting higher particle size, around 1500 nm,
Table 2. Pharmacodynamic Parameters after Oral Administration of Insulin-Loaded Nanoparticles in Both 50 and 100 IU/kg Doses and
Insulin Solution 50 IU/kga
hypoglycemic effect (%) PA (%) Tmax (h) Cmin (% basal glucose)
insulin-loaded nanoparticles (50 IU/kg) 22.0 ( 10.5 5.6 ( 2.6b 14 66.8 ( 10.6
insulin-loaded nanoparticles (100 IU/kg) 27.3 ( 3.8 3.4 ( 0.9 14 64.5 ( 7.3
oral solution (50 IU/kg) 10.8 ( 1.6 1.6 ( 0.7 6 80.8 ( 8.3
a Data represent the mean ( SD, n ) 6 per group. b Statistically significant differences from oral insulin solution control (p < 0.05). Hypoglycemic
effect determined on the basis of AAC. Tmax: time at minimum relative basal glucose concentration in the blood, Cmin: minimum relative basal glucose
concentration in the blood.
Figure 4. Plasma glucose levels after oral administration of insulin-
loaded nanoparticles produced with a DS:Chit mass ratio of 1.5:1 50
IU/kg (b), oral insulin solution 50 IU/kg (O), empty nanoparticles (0),
and suspension of empty nanoparticles in insulin solution 50 IU/kg
(4). Data represent the mean ( SEM, n ) 6 per group.
Figure 5. Serum insulin levels after oral administration of insulin-
loaded nanoparticles produced with DS:Chit mass ratio of 1.5:1 50
(2) and 100 (9) IU/kg doses, and oral insulin solution at 50 IU/kg
(0). Data represent the mean ( SD, n ) 6 per group.
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positive charge, and lower insulin AE. Nevertheless, these
nanoparticles were important for evaluating the potential for
improved mucoadhesivity and the capacity of the higher Chit
composition to transiently open tight junctions between epithelial
cells, improving the absorption of insulin.
The retention of insulin in gastric fluids followed by intestinal
media, simulating the passage from stomach to intestine was
investigated. Figure 2 shows that insulin was retained at gastric
pH for 2 h. Following a pH change to 6.8, a two-step release
pattern was observed, characterized by an initial rapid release
during the first hour followed by a delayed release up to 6 h.
Release of insulin at gastric followed by neutral pH appears to
occur by a slow dissociation of insulin from the Chit/DS
polymers and is pH-dependent. Ideally, insulin remains associ-
ated with nanoparticles in gastric conditions, and it is only
released at the intestinal pH where the absorption potential is
optimal. Compared to other Chit-based nanoparticle formula-
tions, and especially alginate/chitosan nanoparticles,20,34 it may
be deduced that DS prevented premature release of insulin by
providing higher insulin retention capacity than alginate at
gastric pH, predicting lower insulin gastric degradation and
higher availability of active insulin for absorption in the intestine.
The pharmacological effect of insulin loaded nanoparticles
prepared with a DS:Chit mass ratio of 1.5:1 was evaluated in
diabetic rats dosed orally with 50 and 100 IU/kg, and changes
in plasma glucose compared to those dosed subcutaneously with
free insulin at 2.5 IU/kg and orally with empty nanoparticles.
As observed in Figure 3, insulin nanoparticles were found to
be effective in lowering the blood glucose levels at doses of 50
and 100 IU/kg. The hypoglycemic effect appeared more
pronounced after 6 h for a dose of 50 IU/kg, but a faster onset
was observed for a dose of 100 IU/kg. The values of cumulative
hypoglycemic effect found for both groups treated with different
insulin doses showed sustained lowering of the blood glucose
levels, observed 8 h after administration up to 24 h. Both doses
resulted in minimum blood glucose, around 70% of the initial
value, after 14 h. Previously, alginate/chitosan nanoparticles
administered at same insulin dose level30 also reduced blood
glucose levels to their minimum point after 14 h, but to just
over 60% of the initial value. Nevertheless, the hypoglycemic
effect was higher after 24 h for the DS/Chit nanoparticles and
the PA found for both formulations were comparable, as
confirmed from Table 2, reflecting similar relative cumulative
reduction in glucose blood levels. These results suggest that
DS/Chit nanoparticles are able to provide insulin absorption on
a continuous basis and for a longer time period than alginate/
chitosan nanoparticles.
To investigate whether nanoparticles facilitated intestinal
absorption of free insulin, rats were treated orally with insulin
alone, and with empty nanoparticles suspended in insulin
solution (50 IU/kg). A slight decrease in glycemia after
administration of oral insulin solution may be seen in Figure 4
for the first 6 h after administration, returning to basal levels.
The presence of empty nanoparticles did not enhance the minor
hypoglycemic effect of oral insulin solution, and therefore did
not act as insulin absorption enhancers. Only the encapsulation
of insulin into nanoparticles and the resulting protective effect
highlighted the role of nanoparticulate delivery of insulin in
producing a pharmacological response.
DS/Chit nanoparticles appear to stabilize and protect en-
trapped insulin from degradation in the gastrointestinal track
as free insulin did not induce a glycemic response. After
administration, nanoparticles likely reached the upper small
intestine. Due to the mucoadhesive properties of chitosan,
nanoparticles adhere to the intestinal walls, starting the promo-
tion of insulin absorption. In addition, ongoing adhesion is likely
promoted by the viscous lumen and fasted animal conditions.
It is hypothesized that the initial absorption of insulin is related
to the high local insulin concentration favoring diffusion through
the intestinal wall. Direct uptake of insulin has been ascribed
to binding to specific insulin receptors in intestinal enterocytes35-37
following passage to the interstitial space and then to the blood
circulation. It was noted previously that the receptors located
on the upper small intestine were saturated with insulin alginate/
chitosan nanoparticles administered at a dose of 50 IU/kg,30 and
thus the higher insulin concentration gradient at a dose of 100
IU/kg probably was not efficient to promote additional insulin
absorption at this level. Therefore, the increase of physiologic
effect when the dose increased from 50 to 100 IU/kg in the
first 6 h may be understood as faster intestinal insulin absorption
due to the increment of number of nanoparticles that arrive at
the posterior small intestine where they can be directly taken
up by Peyer’s patches.6,38 The direct uptake of nanoparticles is
thought to occur to a lesser extent by enterocytes,6 and mainly
in the Peyer’s patches of the posterior intestine, possible
mechanisms contributing to the total amount of absorbed insulin.
Higher insulin blood levels detected initially for a dose of 100
IU/kg, as seen in Figure 5, confirm the absorption of insulin to
a higher extent. Subsequent continuous absorption of insulin is
probably due to ongoing sustained release of insulin during
nanoparticle adhesion to the intestinal walls, and mainly due to
passage of nanoparticles to the posterior small intestine,
contributing to the plateau level of hypoglycemia. Despite
mucoadhesive properties, nanoparticles probably slide along the
Table 3. Pharmacokinetic Parameters for Serum Insulin Levels after Oral Administration of Insulin-Loaded Nanoparticles in Both 50 and
100 IU/kg Doses and Insulin Solution 50 IU/kga
bioavailability [ng/(mL h)] Tmax (h) Cmax (ng/mL)
insulin-loaded DS/Chit nanoparticles 50 IU/kg 2.46 ( 1.47 8 0.46 ( 0.16
insulin-loaded DS/Chit nanoparticles 100 IU/kg 5.25 ( 2.14 10 0.60 ( 0.20
oral solution (50 IU/kg) 1.75 ( 0.87 1 0.22 ( 0.16
a Data represent the mean ( SD, n ) 6 per group. Bioavailability determined on the basis of AUC. Tmax: time at maximum concentration of insulin in
the blood. Cmax: maximum concentration of insulin in the blood.
Figure 6. Plasma glucose levels after oral administration of different
insulin-loaded nanoparticles prepared with DS:Chit mass ratio of 1:1.5
(9) and 1.5:1(2) 50 IU/kg compared with oral insulin solution (0) 50
IU/kg. Data represent the mean ( SEM, n ) 6 per group.
Oral Bioavailability of Insulin Biomacromolecules, Vol. 8, No. 10, 2007 3057
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intestine maintaining their physical structure. In fact, Chit and
Chit-based microspheres have shown mucoadhesive capacities
in Vitro, and concomitant slow upper small intestinal transit in
ViVo, but this intestinal retention was limited to a few hours39,40
and not affected by the particle size of the dosage form.39 The
arrival of nanoparticles to the posterior intestine probably occurs
in a few hours, and because adhesive properties are maintained,
uptake is promoted.
Compared with the in Vitro simulation, the extent of release
in the gastrointestinal tract may be much less, and thus
nanoparticles must be able to retain significant insulin loading
when taken up. Uptake of the nanoparticles by the M cells on
the Peyer’s patches has been explained as responsible for longer
hypoglycemic response.2,41 Furthermore, possible immunological
consequences after oral insulin administration are believed to
be absent. In fact, the prevalence of anti-insulin antibodies in
diabetic people have been largely absent, mainly as a conse-
quence of improvements in the purification of insulin.42
The hypoglycemic effect after 8 h was observed to be similar
for both doses, different from that observed for the first hours
of assay. It seems that the improvement of absorption was
limited to the first hours when the entrance of nanoparticles to
the posterior intestine was proportional to the number of
nanoparticles administered. Nevertheless, the overall bioavail-
ability of insulin, as outlined in Table 3, clearly demonstrated
that it was higher when insulin was administered orally through
nanoparticle delivery, in a dose of 100 IU/kg, compared with a
dose of 50 IU/kg and insulin solution at 50 IU/kg, suggesting
a relative dose/effect response.
Figure 7. Confocal scanning microscopy images showing the association of FITC-insulin (green) to intestinal tissue (cell membranes in red).
(A) FITC-insulin nanoparticle suspension. (B) Inner apical intestinal section treated with control empty nanoparticles. (C) Transversal section
of intestinal epithelium. Longitudinal sections of anterior (D) and posterior (E) intestinal epithelium treated with insulin-loaded nanoparticles
(500 nm). The intestinal line is demarked by the red line of cellular membranes. Also, green dots corresponding to the FITC-insulin (white
arrows) can be observed both attached to the surface and inside the intestinal wall. The three-dimensional plan shows the internalization of
labeled insulin. Gray lines indicate the plans where pictures were analyzed.
3058 Biomacromolecules, Vol. 8, No. 10, 2007 Sarmento et al.
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To evaluate the potential improvement of insulin absorption
by nanoparticles composed by higher Chit composition, nano-
particles were prepared with a DS:Chit mass ratio of 1:1.5 and
administered orally to diabetic rats. The results plotted in Figure
6 compare the cumulative hypoglycemic effect of the two
different nanoparticle formulations prepared with DS:Chit mass
ratio of 1.5:1 and 1:1.5. Formulation containing a higher fraction
of Chit was able to decrease the blood glucose levels compared
with the single insulin solution. However, only minor differences
in the lowering of glucose levels and total cumulative hypogly-
cemic effect were found between nanoparticles prepared with
DS:Chit mass ratio of 1.5:1 and 1:1.5. In the literature it is well-
established that nanoparticle intestinal translocation increases
when the particle diameter decreases.43 However, it is also
reported that this trend is not absolute. Although lower than
for nanoparticles with 100 nm, the efficiency of nanoparticle
uptake from rat intestinal tissue with Peyer’s patches was very
similar for nanoparticles of 500 nm and particles of 1 and 10
ím.44 Also, the Caco-2 cell uptake of nanoparticles was found
very close for 500 and 1000 nm particles.45 The size range of
nanoparticles is similar to that used in the present study and
thus it is hypothesed that small differences would be expected
between both formulations. In addition, theoretical improvement
of insulin absorption would be obtained by nanoparticles
prepared with a DS:Chit mass ratio of 1:1.5 due to improved
mucoadhesivity because of the higher Chit fraction and reduced
DS. It is possible that nanoparticles with a DS:Chit mass ratio
of 1:1.5 stick strongly within the intestinal layer in the first hours
after administration, resulting in a slightly lower blood glucose
decrease compared to nanoparticles with a DS:Chit mass ratio
of 1.5:1. However, nanoparticles prepared with a smaller faction
of DS are probably less able to retain insulin in intestinal pH
and protect it against degradation,26 suggesting once more the
important role of DS on protection of insulin. Thus, it is possible
that the protection of insulin within nanoparticles made of DS:
Chit mass ratio 1:1.5 decreases compared with those of 1.5:1,
resulting in less insulin absorption after 10 h through nanopar-
ticle uptake.
Investigations on possible insulin absorption mechanisms
were examined using FITC-insulin. Resulting FITC-insulin
loaded nanoparticles with similar mean particle size of insulin-
loaded nanoparticles (500 nm) were administered orally to
diabetic rats and intestinal epithelial sections observed through
confocal microscopy and compared to rats dosed with empty
nanoparticles.
As observed in Figure 7, FITC-insulin nanoparticles were
located between villi (C) and on the surface and inside of
anterior (D) and posterior intestinal epithelium (E). Intestinal
rat section administered with empty nanoparticles (B) is shown
as control where autofluorescence associated with the intestinal
tissue was not observed.
The retention of insulin nanoparticles on the mucosa due to
mucoadhesion and further insulin absorption appears to be
demonstrated by the presence of FITC-insulin on the surface
of villi (C) and on the apical membrane of the intestine (D, E)
3 h after administration. Further investigations revealed the
presence of internalized FITC-insulin within the intestinal wall
(D, E).
The anterior intestine region (D) appears to be less rich in
FITC-insulin than the posterior region, which can indicate that
insulin was internalized by different mechanisms depending on
the depth that nanoparticles crossed the intestinal tract. Also,
nanoparticles on the surface of intestinal mucosa were partially
removed during the rinsing step before membrane staining,
probably decreasing the observed fluorescence. In the anterior
intestine, mucoadhesive nanoparticles probably attached to
intestinal walls favoring the absorption of insulin, as hypoth-
esized above. The mucoadhesive17 and absorption-enhancing
properties of Chit16,46,47 may be fundamental to the insulin
concentration on the surface of the intestinal wall and to its
diffusion through the epithelium, promoting insulin absorption.
Mucoadhesive nanoparticles penetrating the mucous layer are
able to prolong the residence time and released insulin can
interact deeply and permeate the intestinal barrier to the
bloodstream.
The presence of green fluorescence in a great extent on the
posterior intestine (E) seems to predict the presence of FITC-
insulin in a deeper layer than the intestinal surface. The XZ
and XY lateral planes clearly demonstrate that FITC-insulin
is positioned below the apical membrane of the intestine, and
therefore it was able to pass through the surface layer of
enterocytes. Although it is not clear from Figure 7 that insulin
nanoparticles were absorbed through Peyer’s patches pathway,
even though there is no specific fluorescent marker to identify
M cells,48 there is evidence that the posterior ileum is the most
prominent area of Peyer’s patches, and the site where nano-
particles can be absorbed with higher efficacy.49,50
Conclusion
Insulin-loaded DS/Chit nanoparticles produced by polyelec-
trolyte complexation provided markedly enhanced intestinal
absorption of insulin following oral administration. Nanopar-
ticles lowered serum glucose levels of streptozotocin-induced
diabetic rats at insulin doses of 50 and 100 IU/kg up to 67 and
64%, respectively, of their basal glucose level. The hypogly-
cemic effect and insulinemia levels due to insulin nanoparticles
were considerably higher than those obtained from oral insulin
solution and suspension of empty nanoparticles in insulin
solution, revealing 2-3-fold improvement of oral relative
pharmacological availability. In addition, the hypoglycemic
effect was observed for more than 24 h. The mechanism of
insulin absorption seems to be associated with insulin internali-
zation, probably through vesicular structures in enterocytes and
insulin-loaded nanoparticle uptake by Peyer patches, although
no single mechanism could be identified. DS/Chit nanoparticles
demonstrated promise as an oral delivery system for insulin and
potentially for other therapeutic proteins.
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